跳转至内容
Merck
CN

C5145

Sigma-Aldrich

Chlormadinone acetate

≥98%

别名:

17α-Acetoxy-6-chloro-4,6-pregnadiene-3,20-dione, 6-Chloro-17α-hydroxy-4,6-pregnadiene-3,20-dione 17-acetate, 6-Chloro-6-dehydro-17α-acetoxyprogesterone, Gestafortin, Matrol, Menstridyl

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C23H29ClO4
化学文摘社编号:
分子量:
404.93
Beilstein:
2633614
EC 号:
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥98%

表单

powder

SMILES字符串

[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]3(OC(C)=O)C(C)=O)[C@]1([H])C=C(Cl)C4=CC(=O)CC[C@]24C

InChI

1S/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h11-12,16-18H,5-10H2,1-4H3/t16-,17+,18+,21-,22+,23+/m1/s1

InChI key

QMBJSIBWORFWQT-DFXBJWIESA-N

基因信息

human ... PGR(5241)

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Review of progestogenic and related pharmacological effects of chlormadinone acetate.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Roberto Uras et al.
Contraception, 82(2), 131-138 (2010-07-27)
Chlormadinone acetate (CMA) is a progestin compound similar to progesterone, with antiandrogenic properties. In healthy eumenorrheic women, it was demonstrated that the monophasic estroprogestin formulation containing CMA (2 mg) plus ethinyl estradiol (EE) (30 mcg) (EE30+CMA) is efficacious both in
D Altun et al.
Toxicology and industrial health, 27(1), 29-33 (2010-08-18)
In this study, the effects of chlormadinon acetate (CMA) and CMA + nordihydroguaiaretic acid (NDGA) on various developmental stages of Drosophila melanogaster were investigated. Different concentrations of CMA (1.0; 3.0; 5.0 and 10.0 μM/100 mL medium) and CMA + NDGA
Carolina Sales Vieira et al.
Contraception, 86(3), 268-275 (2012-04-03)
Polycystic ovary syndrome (PCOS) is an endocrine disorder associated with metabolic dysfunction and changes in cardiovascular risk markers, and using oral contraceptives (OCs) may exert a further negative effect on these alterations in patients with PCOS. Thus, the primary objective
Mercedes Gómez Vázquez et al.
American journal of clinical dermatology, 12 Suppl 1, 13-19 (2011-09-16)
The diagnosis and management of four cases of dermatological disorders, most of which are related to the endocrine disorder of androgen excess, are presented. Combined oral contraceptives (COCs) may be useful when well-tolerated hormonal therapy and/or when contraception is required.
Valéria A Gomes et al.
Basic & clinical pharmacology & toxicology, 111(3), 211-216 (2012-04-19)
Biochemical markers of cardiovascular disease, including matrix metalloproteinases (MMPs), are altered in women with polycystic ovary syndrome (PCOS), with many of these alterations thought to be due to excess androgen concentrations. Despite oral contraceptives (OCs) being the first-line pharmacological treatment

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持